AtaiBeckley
Manufacturing · Netherlands · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Prof. J.h. Bavincklaan 7, Amstelveen, No...Phone Number
+31 207932536Website
www.ataibeckley.comRevenue
<$5 MillionStock Symbol
ATAIIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About AtaiBeckley
AtaiBeckley is a clinical-stage biopharmaceutical company headquartered in New York and Amsterdam, focused on developing rapid-acting and convenient mental health treatments to transform patient outcomes. Formed through the strategic combination of atai Life Sciences and Beckley Psytech Limited completed in November 2025, the company brings together world-class science and clinical expertise with a pipeline of investigational psychedelic-based neuroplastogens designed to address urgent unmet needs in mental health. AtaiBeckley's lead program is BPL-003, a novel mebufotenin benzoate nasal spray designed to produce rapid and durable antidepressive effects from a single dose for treatment-resistant depression, which has received Breakthrough Therapy designation from the FDA and is Phase 3-ready. The company's diversified pipeline also includes VLS-01, a DMT buccal film for treatment-resistant depression currently in Phase 2 clinical trials, EMP-01, an oral R-MDMA being evaluated for sociaRead more
Popular SearchesAtaiBeckley NVSIC Code 28,283NAICS Code 32,325Ticker NASDAQ: ATAIShow moreAtaiBeckley Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AtaiBeckley your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once AtaiBeckley has new funding data
Earning: See what the market has to say on AtaiBeckley recently announced quarterly report
Website visits: Recent activity has been detected on your website
Click to see if AtaiBeckley had a recent Job posting/layoffs
Check out if AtaiBeckley is spiking on competitors!
Check if AtaiBeckley has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when AtaiBeckley launches new products
Congratulate Masked Content for being promoted to Masked Content at AtaiBeckley
Competitive Alert! Recent activity has been detected by your competitor Masked Content
AtaiBeckley, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined AtaiBeckley as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
AtaiBeckley is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
AtaiBeckley is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about AtaiBeckley.
Most Recent Scoops
Project
AtaiBeckley has designed Reconnect One as a three-arm study (12 mg, 4 mg, and placebo) enrolling approximately 350 patients with a single administration and a four-week primary endpoint, and Reconnect Two as a two-arm study enrolling approximately 230 patients with two administrations two weeks apart and a four-week primary endpoint.
Clinical Operations
Project
AtaiBeckley has announced a subsequent cohort study evaluating two doses of 8 milligrams of BPL-003 administered on a background of SSRIs, with results expected by year-end, intended to generate data supporting the safety and efficacy of adjunctive use for potential label inclusion.
Medical Research, Pharmaceuticals
Project
AtaiBeckley has indicated that the short duration of intense psychedelic experience with BPL-003, approximately 30 to 45 minutes, and VLS-01 may support a reduced acute monitoring requirement post-approval, potentially enabling a label similar to SPRAVATO with the possibility of eliminating the requirement for an in-room monitor.
Pharmaceuticals, Clinical Operations
Project
AtaiBeckley has reported that the safety and tolerability profile of BPL-003 in clinical trials includes class-related adverse events such as nausea, vomiting, headache, and cardiovascular effects, as well as mild to moderate nasal irritation attributable to the intranasal route of administration, which largely resolved prior to the onset of psychedelic effects.
Clinical Operations
Project
Medical Research, Pharmaceuticals, Clinical Operations
AtaiBeckley News & Media
Stock Market Today, July 16: AtaiBeckley Surges on Eli Lilly Acquisition Worth Up To $3.8 Billion
Today, July 16, 2026, the clinical-stage psychedelics developer jumped 33% after Lilly announced a cash deal plus milestone payments.Eli Lilly Buys AtaiBeckley in $3.8 Billion Deal
Acquisition could strengthen its neuroscience growth strategy$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of AtaiBeckley Inc. (NASDAQ: ATAI)
NEW YORK, July 16, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The...Eli Lilly Is Buying AtaiBeckley in $2.8 Billion Deal. What It Means for LLY Stock
Eli Lilly stock rallies on a $2.8 billion acquisition of AtaiBeckley. Here’s why the deal is bullish for LLY shares.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding AtaiBeckley
Sign Up For FreeTo access detailed company insights
AtaiBeckley is a clinical-stage biopharmaceutical company headquartered in New York and Amsterdam, focused on developing rapid-acting and convenient mental health treatments to transform patient outcomes. Formed through the strategic combination of atai Life Sciences and Beckley Psytech Limited completed in November 2025, the company brings togethe... Read More
